Ameriprise
ATRA icon

Ameriprise’s Atara Biotherapeutics ATRA Stock Holding History

Ameriprise’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-66,061
Closed -$2.44M – 3902
2023
Q3 		$2.44M Buy
66,061
+20,116
+44% +$895K ﹤0.01% 2729
2023
Q2 		$1.85M Sell
45,945
-13,250
-22% -$749K ﹤0.01% 2917
2023
Q1 		$4.29M Buy
59,195
+5,858
+11% +$568K ﹤0.01% 2420
2022
Q4 		$4.38M Buy
53,337
+18,434
+53% +$1.92M ﹤0.01% 2379
2022
Q3 		$3.3M Sell
34,903
-8,320
-19% -$935K ﹤0.01% 2518
2022
Q2 		$8.42M Sell
43,223
-11,035
-20% -$1.8M ﹤0.01% 1871
2022
Q1 		$12.6M Buy
54,258
+7,207
+15% +$2.29M ﹤0.01% 1716
2021
Q4 		$18.5M Buy
47,051
+16,972
+56% +$7.14M 0.01% 1478
2021
Q3 		$13.5M Buy
30,079
+415
+1% +$149K ﹤0.01% 1599
2021
Q2 		$11.5M Buy
29,664
+9,088
+44% +$3.24M ﹤0.01% 1825
2021
Q1 		$7.39M Buy
20,576
+7,627
+59% +$3.37M ﹤0.01% 2122
2020
Q4 		$6.36M Sell
12,949
-2,231
-15% -$1.03M ﹤0.01% 2097
2020
Q3 		$4.92M Sell
15,180
-720
-5% -$245K ﹤0.01% 2100
2020
Q2 		$5.79M Sell
15,900
-1,359
-8% -$343K ﹤0.01% 1957
2020
Q1 		$3.67M Buy
17,259
+4,010
+30% +$1.27M ﹤0.01% 2113
2019
Q4 		$5.45M Buy
13,249
+176
+1% +$60.7K ﹤0.01% 2183
2019
Q3 		$4.62M Buy
13,073
+2,734
+26% +$1.02M ﹤0.01% 2252
2019
Q2 		$5.2M Buy
10,339
+137
+1% +$96.7K ﹤0.01% 2234
2019
Q1 		$10.1M Buy
10,202
+4,974
+95% +$4.62M ﹤0.01% 1695
2018
Q4 		$4.54M Sell
5,228
-1,898
-27% -$1.76M ﹤0.01% 2181
2018
Q3 		$7.37M Sell
7,126
-5,111
-42% -$5M ﹤0.01% 2097
2018
Q2 		$11.2M Sell
12,237
-4,737
-28% -$5.09M 0.01% 1640
2018
Q1 		$16.5M Buy
+16,974
New +$15.5M 0.01% 1262

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ameriprise's ATRA Position: Q4 2023 in Review

Ameriprise sold out of Atara Biotherapeutics (ATRA) in Q4 2023, closing a stake of 66,061 shares — an estimated $2.44M sold.

Ameriprise first reported a position in ATRA in Q1 2018 and held it in 23 quarters. The position peaked at $18.5M in Q4 2021. 90 funds tracked by Wall St. Rank hold ATRA as of Q4 2023.

  • Ameriprise reported no remaining Atara Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • Ameriprise sold 66,061 Atara Biotherapeutics shares in Q4 2023, an estimated $2.44M.
  • Ameriprise first reported a position in Atara Biotherapeutics in Q1 2018 and held it in 23 quarters.
  • Ameriprise's Atara Biotherapeutics position peaked at $18.5M in Q4 2021.
  • 90 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2023.

Based on Ameriprise's 13F filing for Q4 2023, filed 14 Feb 2024.